ACTB and ovarian carcinoma: The highest increases of PARP1/ACTB mRNA ratios were induced by the most potent PARP inhibitor, the bilactamic steroid alkylator ASA-B, reaching at 120-fold increase in SKOV-3 and a 42–50-fold increase in UWB1.289, UWB1.289 + BRCA1 and OVCAR-3 human ovarian cancer cells.